ImmunityBio – 2026-01-19 - Increase Confidence 8/10

IBRX – Increase in Days/Weeks

ImmunityBio posted a 700% year-over-year revenue surge in FY2025, driven by ANKTIVA adoption, coinciding with the Saudi FDA’s landmark approval for metastatic NSCLC and NMIBC. This dual catalyst—commercial execution and regulatory expansion—has reignited investor confidence.

Why This Matters

The company’s financial trajectory remains unprofitable, with negative EBIT and free cash flow, but the 700% revenue growth and $113M in product sales signal a major inflection in commercial adoption, particularly for ANKTIVA. The Saudi FDA approval not only validates subcutaneous administration but also opens a new international market, providing near-term revenue diversification and de-risking the clinical pathway ahead of Q2 2026 Phase 2b enrollment completion. With cash reserves at $242.8M, the firm has runway to execute, making this growth phase less funding-dependent.

Key Insights

• Revenue Growth: $113M preliminary FY2025 revenue, up ~700% YoY; Q4 alone reached $38.3M
• News Impact: SFDA approval for ANKTIVA in NSCLC and NMIBC — first global nod for NSCLC, enabling ex-U.S. commercialization
• Risk/Offset: Negative free cash flow ($-398M TTM) and lack of profitability offset gains, though cash runway reduces near-term dilution risk

Practical Implications

• Bull Case: Regulatory momentum and sales growth attract institutional re-rating; stock reaches $7.50+ by February
• Bear Case: High cash burn persists, and U.S. FDA approvals lag, triggering profit-taking after recent 39.75% surge
• Confidence: 8/10 – Strong revenue validation and new approvals outweigh near-term profitability concerns

Prediction: increase

Reference:

• https://www.pharmiweb.com/press-release/2026-01-15/immunitybio-reports-continued-execution-and-sales-momentum-with-113-million-of-preliminary-net-prod
• https://finance.yahoo.com/quote/IBRX/
• https://timothysykes.com/news/immunitybioinc-ibrx-news-2025_11_30/